Nykode Therapeutics Asa · OSL:NYKD
Nykode Therapeutics Asa — Investor Presentation (August 2026)
73 slides from Nykode Therapeutics Asa's investor presentation, August 2026
Slide 1: Company Presentation
Company Presentation August 2026
Slide 2: Forward-looking statement
Forward-looking statement This announcement and any materials distributed in connection with this presentation may contain certain forward- looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company’s current expectations and assumpt
Slide 3: INT field validated with Moderna's positive Phase 3 data in adjuvant melanoma
Individualized Neoantigen Therapy (INT) field validated with Moderna’s positive Phase 3 data in adjuvant melanoma Phase 3 INTerpath-001* results What the positive data proves What it means for Nykode • Moderna and Merck reported positive Phase 3 • Cancer vaccines can drive an effective anti- • Valid
Slide 4: Nykode Therapeutics - Highlights
Nykode Therapeutics - Highlights NYKODE THERAPEUTICS (OSE: NYKD.OL) Antigen-presenting cell-targeted immunotherapy platform Precision immune activation for oncology and immune modulation for autoimmune diseases Clinical assets Abi-suva (HPV16-specific off-the-shelf vaccine) Current program suppo
Slide 5: Three key assets with extensive market potential
Three key assets with extensive market potential Abi-Suva (VB10.16): addressing markets with blockbuster potential in multiple HPV16+ cancer types • High conviction from 3 trials across different indications showing strong and durable clinical response correlated with antigen specific immune respons
Slide 6: Nykode pipeline & completed trials
Nykode pipeline & completed trials Abi-Suva (VB10.16) DNA-based therapeutic vaccine · HPV16-driven cancers - fully owned Study Indication Combination Phase Status Key finding / milestone VB-C-01 High-grade cervical intraepithelial neoplasia (n = 34) - Ph I/II FIH Completed Well-tolerated; early sign
Slide 7: Well-positioned to execute strategy and meet inflection points
Well-positioned to execute strategy and meet inflection points Cash runway H2 2026 2027 Cash runway into 2028-2029* Full focus on enrolment in Abili-T Abili-T first interim analysis (2027) including expanding number of Cash runway exceeding countries and sites Additional peer data readout significan
Slide 8: Nykode executive management
Nykode executive management Experienced and international management team Michael Engsig Agnete Fredriksen Harald Gurvin Louise Stubbe Jakob Rasmussen CEO CSO & BD CFO CLO CTO Nykode Therapeutics | Company presentation Presentation -- August August 2026 2026 8
Slide 9: Targeting APCs drives precise immune response tailored to disease setting
Targeting APCs drives precise immune response tailored to disease setting APCs play key role in immune regulation Nykode Modular Design to target APCs • Targets antigen-presenting cells (APCs), the key regulators of immune responses Targeting unit → binds relevant APCs • Nykode technology delivers a
Slide 10: Focused execution on oncology and autoimmune diseases
Focused execution on oncology and autoimmune diseases What Nykode’s proprietary APC targeting technology Core Focus Areas • Antigen- • Abi-Suva specific • VB10.NEO immune Oncology Auto-immune tolerance platform Opportunity Infectious Allergy Transplants Nykode Therapeutics | Company presentation - A
Slide 11: Oncology
Oncology Nykode Therapeutics | Company presentation - August 2026 11
Slide 12: Nykode's cancer vaccine platform induces a rapid, robust and long-lasting CD8 T cell response
Nykode’s cancer vaccine platform induces a rapid, robust and long-lasting CD8 T cell response against cancer cells MECHANISM OF ACTION OF DNA PLASMID EXPRESSING ACTIVE FUSION PROTEIN FOR T CELL INDUCTION VIA APC Nykode Therapeutics | Company presentation - August 2026 12
Slide 13: VB10.NEO Individualized NeoAntigen Therapy
VB10.NEO Individualized NeoAntigen Therapy Nykode Therapeutics | Company presentation - August 2026 13
Slide 14: Individualized Neoantigen Therapy (INT)
Individualized Neoantigen Therapy (INT) 5. Treatment with 1. Biological Material INT Tumor biopsy & blood Personalized vaccines targeting tumor-specific mutations sample Clinically Validated Modality • First positive Phase 3 for an INT: Merck & Moderna's INTerpath-001 (Aug 2026) Neoantigens • Tumor-
Slide 15: Individualized Neoantigen Therapy (INT) is here to stay
Individualized Neoantigen Therapy (INT) is here to stay Nykode has the most attractive unencumbered assets that can compete in this space Phase 3 INTerpath-001 What this changes for the field of cancer vaccines 1,137 patients, completely resected stage IIB–IV melanoma Cancer vaccines are now de-risk
Slide 16: VB10.NEO can find the targets, generate the responses, and be delivered on time
VB10.NEO can find the targets, generate the responses, and be delivered on time to treat a range of indications Finding the right neoantigen targets Generating responses that make a difference Timely delivery and safe for combination • High-mutation tumors (melanoma, NSCLC): almost • A measurable im
Slide 17: VB10.NEO Clinical Proof-of-Concept
VB10.NEO Clinical Proof-of-Concept Robust immune activation in heavily pre-treated patients N-01 (Phase 1/2a) N-02 (Phase 1b) Earlier line, longer exposure Later-line, heavily pre-treated, multi-tumor Strong Vaccine-Induced Immune Reponses Patients 41 Patients 26 100 • 100% of patients in N- 88 02 s
Slide 18: NeoSELECT: clinically proven neoantigen selection across more than ten indications
NeoSELECT : clinically proven neoantigen selection across more than ten indications • The proprietary AI-driven platform, NeoSELECTTM systematically prioritizes the most immunogenic neoantigens • Validated in clinical trials across multiple tumor types, including tumor types with low TMB* • Clear co
Slide 19: A neoantigen vaccine that targets antigen-presenting cells and improves T cell responses
The platform: a neoantigen vaccine that targets antigen-presenting cells and improve T cell responses Improved T cell responses compared to antigen alone 5ug 10ug Targeting unit P = 0.03 10000 4000 P < 0.001 Mean IFNγ SFU/106 splenocytes Mean IFNg SFU/106 splenocytes • Attracts and binds APCs 8000 3
Slide 20: To our knowledge, the only INT to link immunogenicity to survival
To our knowledge, the only INT to link immunogenicity to survival Antigen-specific immunogenicity correlated with overall survival (OS) in the N-01 trial In patients with low baseline immunogenicity, more de-novo immune responses led to improved overall survival Baseline low & de-novo high Baseline
Slide 21: Optimized manufacturing process has a turnaround time of less than 6 weeks
Our current optimized manufacturing process has a turnaround time (TAT) of less than 6 weeks Key improvements: Manufacturing Time (weeks) 18 • Drug substance and drug product manufacturing processes consolidated under one roof. Optimized slot utilization and shipment timelines 14 • Improved DNA isol
Slide 22: Simpler pDNA production compared to mRNA positions VB10.NEO competitively
Simpler pDNA production and simpler manufacturing process compared to mRNA positions VB10.NEO competitively in the INT field High potential for fast turn-around-time and simpler manufacturing process compared to mRNA pDNA Fermentation DNA Fill Product QA and Purification release mRNA Fermentation DN
Slide 23: A second-generation concept further enhances T cell responses
A second-generation concept further enhances T cell responses MC38 model B16F10 model 0.5ug dose 2.5ug dose 2.5ug dose 7.5ug dose ✓ Nykode’s vaccine 15000 P = 0.001 14000 P = 0.005 technology delivers Mean IFN-γ+ SFU/106 splenocytes Mean IFN-γ+ SFU/106 splenocytes 12000 potent immunogenicity 12000 P
Slide 24: Key takeaways from VB10.NEO
Key takeaways from VB10.NEO Moderna’s positive Phase 3 for INTerpath-001 has validated the field Two completed trials across more than 10 tumor types, 88–100% of patients responding, and a clean safety profile Immunogenicity correlated with overall survival, to our knowledge, uniquely in this class
Slide 25: Lead candidate: Abipapogene Suvaplasmid (Abi-Suva)
Lead candidate: Abipapogene Suvaplasmid (Abi-Suva) HPV16 driven cancer types Nykode Therapeutics | Company presentation - August 2026 25
Slide 26: Understanding HPV and HPV+ cancers
Understanding HPV and HPV+ cancers Human papillomavirus (HPV) is a common DNA virus; high-risk strains can drive cancer HPV16-driven HPV16 is the most prevalent oncogenic subtype cancers: a defined and growing market Tumors express viral antigens not found in normal cells → Clear targets for immune-
Slide 27: Abi-suva: HPV16+ Immunotherapy
Abi-suva: HPV16+ Immunotherapy Targeting unit CCL3L1 Off-the-shelf therapeutic DNA-based cancer immunotherapy against HPV16-induced malignancies Abi-suva Off-the-shelf immunotherapy Dimerization unit HPV16 is the most prevalent oncogenic HPV strain targeting oncogenic IgG Fc derived viral antigens
Slide 28: Clinical proof of concept across HPV16+ cancers
Clinical proof of concept across HPV16+ cancers Key Achievements for Abi-suva Future near-term milestones • Expanding the number of countries and sites in Patients treated with abi-suva show ~100 Abili-T trial consistent clinical activity across 3 HPV16+ indications (C-01, C-02, C-03) • 2027 - inter
Slide 29: Current focus of abi-suva is 1L r/m HNSCC with potential to expand
The current focus of abi-suva is 1L r/m HNSCC with the potential to expand to additional indications and lines of treatment Current focus of abi-suva Future potential for abi-suva 1L r/m HNSCC HPV16+ driven cancers Incidence of HPV16+ driven HNSCC cancers Incidence of HPV16+ driven cancers in EU in
Slide 30: Abi-suva shows strong and consistent clinical effect across several trials
Abi-suva shows strong and consistent clinical effect across several trials and HPV16 driven indications Consistent overall response rate (ORR) improvement compared to CPI monotherapy across indications Objective response rate (ORR) of abi-suva in combination with CPI compared to historical CPI monot
Slide 31: Abi-suva shows strong and consistent clinical effect across several trials
Abi-suva shows strong and consistent clinical effect across several trials and HPV16 driven indications Overall response rate (ORR) indicates a strong clinical effect of abi-suva VB-C-03 (1L r/m Head and Neck Cancer) VB-C-02 (2L+ Cervical Cancer) Abi-suva in combination with pembrolizumab Abi-suva i
Slide 32: Strong overall survival in 2L+ cervical cancer
Strong overall survival in 2L+ cervical cancer C-02 trial Overall survival of 24.7 mos in PD-L1+ patients Overall survival is longer than CPI monotherapy treated with abi-suva + atezolizumab for 12 historic controls months mOS compared to SOC 24,7 ~109% 13,9 10,6 11,0 24,7 13,9 10,6 11,0 Abi-suva +
Slide 33: Strong monotherapy activity observed in HSIL patients
Strong monotherapy activity observed in HSIL patients C-01 trial Patients showed consistent reduction in lesion size and regression of lesion severeness • Strong monotherapy efficacy observed in premalignant cervical lesions (CIN2/3, HSIL patients) • Safe and well tolerated C-01 data: Hillemanns et
Slide 34: Immune responses strongly correlate with clinical outcomes across trials
Immune responses strongly correlate with clinical outcomes across trials C-02 2L+cervical cancer in C-01 HSIL patients monotherapy combination with atezolizumab 1500 1000 p=0.0113 500 250 • HPV16-specific T-cell responses associated with lesion size reduction SFU/106 PBMC 200 150 • Correlation obser
Slide 35: First patient dosed in randomized Phase 2 Abili-T trial
First patient dosed in randomized Phase 2 Abili-T trial with first interim data expected in 2027 Trial design Key inclusion criterion Treatment Endpoints ORR Abipapogene suvaplasmid + pembrolizumab PFS • HPV16+ r/m HNSCC DOR • PD-L1+ R RMDOR • Measurable disease (1:1) DCR • ECOG PS 0-1 OS • GRIm 0-1
Slide 36: Key takeaways from abi-suva
Key takeaways from abi-suva Encouraging data from three clinical trials across different HPV16+ indication demonstrating promising efficacy and favorable safety profile Initiated validating randomized phase II trial (Abili-T) in 1L r/m HNSCC High market potential for HNSCC and additional HPV16+ indi
Slide 37: Antigen-Specific Immune Tolerance
Antigen-Specific Immune Tolerance Nykode Therapeutics | Company presentation - August 2026 37
Slide 38: Induction of antigen-specific immune tolerance by targeting epitopes to specific APCs
Induction of antigen-specific immune tolerance by targeting disease causing epitopes to specific APCs TARGETING SPECIFIC TOLERANCE INDUCTION Therapy delivered as rec. protein, or as pDNA through cell transfection APC-targeted B cells Effector Therapy B cell APCs Regulatory Regulatory T cell T cell D
Slide 39: Key highlights of Nykode's APC ASIT Technology
Key highlights of Nykode’s APC ASIT Technology Strong and durable efficacy across disease models – therapeutic and preventative Modular APC-targeting platform allows unique customization for tailored immune control Unprecedented induction of antigen-specific regulatory T cells, suppression of effect
Slide 40: Targeting APCs to ensure precise antigen-specific immune tolerance
Targeting APCs to ensure precise antigen-specific immune tolerance with proven modality and convenient administration Module 1: Multiple targeting units1 for receptors on tolerizing APCs identified including natural ligands and other targeting molecules Module 2: Dimerization unit to facilitate stro
Slide 41: Long lasting efficacy demonstrated across autoimmune disease models
Long lasting efficacy demonstrated across autoimmune disease models Targeted 4 Therapy PBS ✱✱ EAE score (0-8) 200 3 EAE Model – Later Therapeutic Treatment 160 AUC (5-35) 2 120 80 • Treatment after symptom onset results in strong and durable 1 40 therapeutic effect 0 0 Targeted PBS 10 12 14 16 18 20
Slide 42: APC targeting drives precise and potent antigen-specific immune engagement
42 APC targeting drives precise and potent antigen-specific immune engagement Antigen-specific Treg induction ✱✱✱✱ ✱✱✱✱ Differentiated T Cell Engagement & Treg Targeted 5 APC Non-targeted 10 of CD4+Thy1.2+ T cells Induction 8 ✱✱✱ %Foxp3+CD25+ 6 • APC targeting enables precise and potent antigen-spec
Slide 43: Multi-layered immune regulation demonstrated across key endpoints
Multi-layered immune regulation demonstrated across key endpoints Antigen-specific auto-antibodies anti-MOG (35-55) IgG ✱ 1000 Therapeutic Reduction of Auto-Antibodies MOG-specific IgG (µg/mL) 800 • Significant reduction of disease specific auto-antibodies in EAE mice (10 600 µg dose per timepoint)
Slide 44: Regulation of disease in the disease relevant organs
Regulation of disease in the disease relevant organs SIGNIFICANTLY REDUCE THE NUMBER OF BOOSTS PANCREATIC ISLET CD4+ T CELLS WITH A CNS-INFILTRATING CELLS IN EAE REGULATORY PHENOTYPE IN NOD (T1D) CD4+ cells Distribution of CD4+FOXP3+Tim3+ ✱✱✱✱ cell density ✱✱✱ 1.2×10 5 100 mg of spinal cord Cell num
Slide 45: Multiple translational enablers support rapid clinical progression
Multiple translational enablers support rapid clinical progression Paralysis PBS Targeted Therapy, i.v. Subcutaneous Administration Targeted Therapy, s.c. 5 • S.C. delivery provides equivalent therapeutic benefit to I.V. in the EAE model EAE score (0-8) 4 Day 28: 3 • Translational and clinically ben
Slide 46: Key takeaways from ASIT
Key takeaways from ASIT Promising data show long-lasting efficacy across autoimmune disease models Consistent platform-driven efficacy across all relevant immune cell compartments and in affected organs Recombinant protein format delivered through convenient route of administration In house AI/ML ex
Slide 47: AI driven drug design
AI driven drug design Nykode Therapeutics | Company presentation - August 2026 47
Slide 48: How AI is Embedded in Nykode's Platform
How AI is Embedded in Nykode’s Platform Our Competitive Differentiation Utilizing AI NeoSELECT Construct Screening Predictive Design VB10.NEO Platform-wide Quality Assurance Proprietary AI algorithm selects the AI-driven design and screening Predictive modeling improves construct quality most immuno
Slide 49: Outlook
Outlook Nykode Therapeutics | Company presentation - August 2026 49
Slide 50: Well-positioned to execute strategy and meet inflection points
Well-positioned to execute strategy and meet inflection points Cash runway H2 2026 2027 Cash runway into 2028-2029* Full focus on enrolment in Abili-T Abili-T first interim analysis (2027) including expanding number of Cash runway exceeding countries and sites Additional peer data readout significan
Slide 51: Appendix
Appendix Nykode Therapeutics | Company presentation - August 2026 51
Slide 52: ABI-SUVA
ABI-SUVA Nykode Therapeutics | Company presentation - August 2026
Slide 53: C-02: VB10.16 plus atezolizumab in advanced cervical cancer
C-02: VB10.16 plus atezolizumab (Tecentriq®) in advanced cervical cancer A Multi-Centre, Single Arm, Open-label Phase 2a Trial of the Combination of VB10.16 and atezolizumab in Patients with Advanced or Recurrent, Non-resectable HPV16 Positive Cervical Cancer (NCT04405349) Objectives: Safety/toler
Slide 54: Powerful long-lasting responses aligned with mDOR n.r.
Powerful long-lasting responses aligned with mDOR n.r. C-02 trial All (n = 47) By PD-L1 status (n = 40) Note: 7 out of 47 responders had PD-L1 unknown status, 40 out of 47 had known PD-L1 status C-02 data: Hillemanns et al, JITC 2025 13(1), Safety and efficacy of the therapeutic DNA-based vaccine VB
Slide 55: VB-C-03 – dose escalation in 1L r/m HNSCC
VB-C-03 – dose escalation 3 to 9 mg in 1L r/m HNSCC Combination treatment of VB10.16 + pembrolizumab in 1L HPV16+, PD-L1+ r/m HNSCC Phase 1 Dose escalation phase 9 mg 9m g 9 mg • Recruitment finalized RP2D* analysis 9 9 9 mg mg mg • All doses safety cleared VB10.16 dosing 6 6 6 mg mg mg • First prel
Slide 56: VB10.NEO
VB10.NEO Nykode Therapeutics | Company presentation - August 2026
Slide 57: Strong immune responses across basket trials with heavily pre-treated patients
Strong immune responses across 2 basket trials with heavily pre-treated patients N-01 and N-02 both show vaccine induced immune response N-01 100 100% of patients in N-02 showed vaccine- N-02 85 85 88 induced immune responses, even in heavily pre-treated late-stage patients after few 58 vaccinations
Slide 58: Vaccination expands breadth of neoantigen immune responses over time
Vaccination results in an expanded breadth of neoantigen immune responses that increase in magnitude over time N-01 clinical trial Breadth of Responses Magnitude of Responses Vaccine-induced responses Vaccine-induced responses (de-novo & amplified) (de-novo & amplified) Number immunogenic neoantigen
Slide 59: Immune responses are durable up to a year following the last vaccination
Immune responses are durable up to a year following the last vaccination Durable responses to treatment (TCRseq) Durable responses to vaccination (ELISpot) vaccinations Nykode Therapeutics | Company presentation - August 2026 59
Slide 60: Antigen-Specific Immune Tolerance
ANTIGEN-SPECIFIC IMMUNE TOLERANCE Nykode Therapeutics | Company presentation - August 2026
Slide 61: Effective and durable disease protection in the EAE model
Effective and durable disease protection in the EAE model Long lasting Efficacy EFFECT OF NYKODE THERAPY IN EAE MODELS Targeted Therapy Paralysis ✱✱ Targeted Weight 5 60 ✱✱ 23 Therapy 1 EAE score (0-8) 22 4 MOG(27-63) AUC (5-20) Weight (g) PBS 40 21 MOG 3 20 (27-63) 2 20 19 18 Daily clinical scores
Slide 62: Even treatment after disease onset results in strong durable effect
Even treatment after disease onset results in strong and Long lasting durable therapeutic effect Efficacy Targeted Therapy EAE MODEL – LATER THERAPEUTIC TREATMENT Targeted 4 Therapy MOG PBS ✱✱ EAE score (0-8) 200 (27-63) 3 160 AUC (5-35) 2 120 Daily clinical scores (5-60) 80 Score >/= 1 1 & 3 days l
Slide 63: Effective and durable disease prevention in the NOD (T1D) model
63 Effective and durable disease prevention also seen in Long lasting the NOD (T1D) model Efficacy Bi-weekly glucose monitoring Week 16 of treatment Wk 0 Weekly glucose monitoring Week 26 termination of study 9 wk old Therapy pDNA injection i.m. NOD mice Dosing once weekly Remove treatment NOD DIABE
Slide 64: Precision APC targeting enables antigen-specific T cell engagement and Treg induction
64 Precision APC targeting enables potent and differentiated APC Targeting antigen-specific T cell engagement and Treg induction ADOPTIVE TRANSFER OF MOG-SPECIFIC CD4+ T CELLS MOG (27-63) APC Non-targeted Therapy ✱✱✱✱ Targeted 5 ✱✱✱✱ Targeted 5 10 of CD4+Thy1.2+ T cells Targeted 4 ✱✱✱ 8 %Foxp3+CD25+
Slide 65: APC-directed targeting unit is required for reversal of EAE disease
65 The APC-directed targeting unit is required for effective APC Targeting reversal of EAE disease in symptomatic mice EAE MODEL – LATER THERAPEUTIC TREATMENT MOG Targeted Therapy 3 APC PBS (27-63) Non-targeted Therapy Targeted Therapy 4 Non-targeted ✱✱✱ Therapy 5 ✱ 90 EAE score (0-8) 4 Day 28 AUC (
Slide 66: Therapeutic reduction of auto-antibodies in EAE mice
Therapeutic reduction of auto-antibodies in EAE mice Immune regulation EAE MODEL – REDUCTION OF AUTO-ANTIBODIES APC anti-MOG (35-55) IgG ✱ 1000 MOG-specific IgG (µg/mL) 800 600 MOG MOG (27-63) (27-63) 400 Targeted Non-targeted Therapy Therapy 200 Daily clinical scores 0 er ted er ted S day 0 day 32
Slide 67: Simultaneous induction of inhibitory T cells and suppression of effector responses
Simultaneous induction of inhibitory T cells and suppression Immune of antigen-specific effector responses regulation EAE MODEL - T CELLS Day 12 post EAE induction: MOG-recall splenocytes MOG Th1.17 cells IFN-γ Lag3 (27-63) ✱ ✱✱✱✱ ✱ Targeted 3 1×10 5 6 Therapy of CD4+ T cells % IFNγ+IL-17+ 8×10 4 of
Slide 68: Regulation of disease in the disease relevant organs
Regulation of disease in the disease relevant organs Immune regulation SIGNIFICANTLY REDUCE THE NUMBER OF BOOSTS PANCREATIC ISLET CD4+ T CELLS WITH A CNS-INFILTRATING CELLS IN EAE REGULATORY PHENOTYPE IN NOD (T1D) CD4+ cells Distribution of CD4+FOXP3+Tim3+ ✱✱✱✱ cell density ✱✱✱ 1.2×10 5 100 mg of sp
Slide 69: Subcutaneous administration delivers equivalent therapeutic benefit
Subcutaneous administration delivers equivalent Fast track therapeutic benefit to clinic EAE model – LATE THERAPEUTIC DELIVERY PBS Targeted Therapy, i.v. Targeted Therapy, s.c. MOG 5 (27-63) Targeted Therapy 4 EAE score (0-8) 3 Day 28: Daily clinical scores ****p<0.0001 ***p<0.001 2 day 0 day 28 1 E
Slide 70: Human APC binding validates translational feasibility
70 Human APC binding validates translational feasibility Fast track to clinic Binding of Nykode APC Targeted Therapy to human APCs ➢ Human APC binding at low APC APC nanomolar levels differentiates targeted therapy and supports fast clinical progression Non-targeted Therapy 1000 nM APC 1 APC 2 Targe
Slide 71: Modular biologic. Multi-antigen power.
Modular biologic. Multi-antigen power. Fast track to clinic Nykode’s APC-targeted proteins leveraging a modality with long-standing regulatory and manufacturing precedent Built for scale: a platform manufacturable on standard biologics infrastructure Simplified CMC vs competing formats, accelerating
Slide 72: AI-driven design and selection framework delivers multi-antigen constructs
Nykode AI-driven design and selection framework delivers Fast track high-yield, high-quality multi-antigen constructs to clinic Model-S: Model-F: In-silico constructs 3D structural High-throughput Features extraction generation prediction T1D example: screening and explainability 5 antigens 18 pepti
Slide 73: END OF PRESENTATION
END OF PRESENTATION Nykode Therapeutics | Company presentation - August 2026
Nykode Therapeutics — Investor Presentation (August 2026) on 6ix